

Zinplava™ (bezlotoxumab)

When requesting Zinplava™ (bezlotoxumab), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved compendial uses and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-approved indication¹

Indicated to reduce recurrence of *Clostridium difficile* infection in individuals who are receiving antibacterial drug treatment for *Clostridium difficile* infection and are at a high risk for *Clostridium difficile* infection recurrence.

Approved Off-label Compendial uses²

- No off-label uses meet evidence standards

Coverage Guidelines¹

Clostridium difficile infection

The individual must meet **all** of the following criteria for approval:

- Receiving antibacterial drug treatment for *Clostridium difficile* infection
- At high risk for *Clostridium difficile* infection recurrence
- Has **not** previously received Zinplava™ (bezlotoxumab)

Approval duration: One dose

Additional Information for Prescribers¹

- In individuals with a history of congestive heart failure, Zinplava™ (bezlotoxumab) should be reserved for use when the benefit outweighs the risk.

References

1. Zinplava™ prescribing information. Whitehouse Station, NJ: Merck and Company, Inc: Revised October 2016. https://www.merck.com/product/usa/pi_circulars/z/zinplava/zinplava_pi.pdf. Accessed January 30, 2017.
2. Klasco RK (Ed): DRUGDEX® system. Thomson Micromedex, Greenwood Village, CO. Accessed January 30, 2017. <https://www.micromedexsolutions.com>.